Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note released on Sunday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

BTX stock opened at $0.21 on Friday. The firm has a market capitalization of $12.07 million, a P/E ratio of -0.79 and a beta of 4.61. The business’s 50-day moving average is $2.15 and its two-hundred day moving average is $1.79. Brooklyn ImmunoTherapeutics has a 1 year low of $0.17 and a 1 year high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.